Apellis Pharmaceuticals
APLS
APLS was delisted on the 13th of May, 2026.
48 hedge funds and large institutions have $375M invested in Apellis Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 8 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
10% more capital invested
Capital invested by funds: $340M → $375M (+$35.2M)
4% more funds holding
Funds holding: 46 → 48 (+2)
2.54% more ownership
Funds ownership: 31.29% → 33.83% (+2.5%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.6M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$7.33M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.28M |
| 4 |
BlackRock
New York
|
+$2.65M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$11.1M |
| 2 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
-$5.81M |
| 3 |
Jennison Associates
New York
|
-$4.48M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.06M |
| 5 |
AllianceBernstein
Nashville,
Tennessee
|
-$1.84M |
APLS Hedge Fund Activity: Q1 2018 in Review
48 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2018, worth a combined $375M — up 10% from $340M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new APLS positions and 8 closed out — a net gain of 2 holders — while 17 added to existing stakes and 12 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $13.6M. The largest seller was Deerfield Management, exiting entirely with an estimated $11.1M sold.
- 48 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2018, up from 46 in Q4 2017.
- Funds reported $375M of Apellis Pharmaceuticals stock for Q1 2018, up 10% quarter-over-quarter.
- 10 funds opened new Apellis Pharmaceuticals positions in Q1 2018 and 8 closed out, a net change of +2 holders.
- The largest Apellis Pharmaceuticals buyer in Q1 2018 was Fidelity Investments, an estimated $13.6M added.
- The largest Apellis Pharmaceuticals seller in Q1 2018 was Deerfield Management, an estimated $11.1M sold.
Based on aggregated 13F filings for Q1 2018.